In short
Clinical trials investigating IBANDRONIC ACID are studying bone health treatments in people with osteogenesis imperfecta, a condition that makes bones break more easily. These trials look at whether treatment plans can lower fracture risk and how well they work compared with usual care. They also include adults and other patients receiving different bone medicines as part of study care.
Key points
- Clinical trial data for IBANDRONIC ACID are linked to research in osteogenesis imperfecta, a condition that causes fragile bones. The main study listed is a Phase 3 interventional trial with 360 planned participants. Its main goal is to measure how many people have a fracture confirmed by x-ray or other imaging. The study compares a treatment plan with standard care, which may include no active treatment or bisphosphonates. The trial is completed, and it focuses on fracture prevention in people with this bone disorder.
Trial overview
The trial record linked to IBANDRONIC ACID is a completed interventional study, which means researchers gave study treatments and then measured what happened. The study ID is 2024-519705-36-00 and it was run as a Phase 3 trial with 360 planned participants.
Although the trial title lists several bone medicines, the record shows that IBANDRONIC ACID was one of the study drugs included in the intervention list.
Condition studied
The trial studied osteogenesis imperfecta, a condition that makes bones fragile and easier to break. This is why the main focus of the study was fracture prevention and bone health.
Study design and phase
This was a Phase 3 study, which is a later stage of clinical research used to test how well a treatment works in a larger group of people. The study was event-driven, meaning it was planned to continue until a set number of fracture events had occurred.
The primary outcome was expected to be reached after an average follow-up of 62 months, based on the number of fractures observed.
Who participated
The trial planned to include 360 participants. The source data do not give a more detailed age range or other eligibility rules, so the safest description is that the study involved people with osteogenesis imperfecta who were suitable for this Phase 3 bone study.
What the study measured
The main endpoint was the proportion of participants experiencing a clinical fracture that was confirmed by x-ray or other imaging. An endpoint is the main result a trial measures to see whether the treatment works.
This endpoint is important because fractures are the key problem in osteogenesis imperfecta, and confirmed imaging helps make sure the outcome is counted correctly.
Treatment comparison and standard care
The brief summary says the study compared a treatment plan of teriparatide followed by zoledronic acid with standard care. Standard care in this trial could mean no active treatment or treatment with bisphosphonates, depending on patient and provider preference.
The intervention list also included several bone medicines, including IBANDRONIC ACID, but the source does not explain the exact role of each listed medicine in the final comparison.
What these trial results mean for patients
For patients, the most important point is that this research was designed to see whether a treatment strategy could lower the chance of broken bones in people with osteogenesis imperfecta. Because the trial is completed, the study question has already been tested, but the source data provided here do not include the final results.
The trial does not provide enough detail to say that IBANDRONIC ACID alone was the only study treatment, so it should be understood as one of the listed medicines in a broader bone research setting.